KBC Group NV increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 54.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...
JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They ...
Learn more about whether Protagonist Therapeutics, Inc. or Twist Bioscience Corporation is a better investment based on ...
Learn more about whether Protagonist Therapeutics, Inc. or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
7h
Investor's Business Daily on MSNStocks Generating Improved Relative Strength: Protagonist TherapeuticsProtagonist Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results